LIMNW — Liminatus Pharma, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1971387 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -1,378,908 -1,407,259 3,403,702 3,017,096 3,103,090
Mar 2026 0 — -1,100,898 -1,123,714 2,790,249 1,907,674 2,922,845
Dec 2025 0 — -884,211 -8,168,927 512,795 337,655 10,327,485
Sep 2025 0 — -701,170 -1,823,351 1,342,409 724,502 2,988,172

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-3,972,747
Investing CF
$-13,108
Financing CF
$5,664,729
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-41,402,706
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-12,447,666
Pretax Income TTM
$-12,523,251
Interest Exp TTM
$75,585
Analysts
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -2,967,812 -10,206,517 512,795 10,327,485 -9,814,690 -9,963,318
Dec 2024 0 -3,329,953 -3,546,309 5,408,859 24,748,922 -19,340,063 -1,451,066
Dec 2023 0 -4,819,000 -4,984,000 2,242,000 18,036,000 0 -3,345,000
Dec 2022 0 -2,709,000 -2,928,000 6,843,000 17,653,000 0 -869,000

TTM Snapshot

Revenues TTM
$52,206
NetIncome TTM
$-12,850,522
OpCashFlow TTM
—
Assets (Latest)
$3,403,702
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
AMGN AMGEN INC $247.70B $457.93 —
GILD GILEAD SCIENCES, INC. $211.18B $170.26 —
MRNA Moderna, Inc. $82.56B $206.80 —
ARGX ARGENX SE $58.92B $947.52 —
BIIB BIOGEN INC. $37.07B $250.79 —

News headlines (Yahoo Finance, 1h cache)

Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
2026-08-18 20:01 · Yahoo
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
2026-08-13 11:15 · Yahoo
Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline
2026-06-30 20:30 · Yahoo
Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds
2026-06-03 12:30 · Yahoo
Liminatus Pharma Announces Nasdaq Delisting Notification
2026-05-22 00:28 · Yahoo
Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
2026-09-29 13:00 · Yahoo
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
2026-08-24 12:00 · Yahoo
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody
2026-03-17 12:08 · Yahoo
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
2026-02-17 13:44 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.